Key clinical point: Tanezumab improved pain and physical function outcomes at 24 weeks with minimal cases of rapidly progressive osteoarthritis.
Major finding: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and WOMAC physical function subscale scores were significantly improved, compared with placebo in the two tanezumab (2.5 mg and 5 mg) dose groups.
Study details: A phase 3, randomized, double-blind, parallel-group, placebo-controlled study of 849 patients with moderate to severe, difficult-to-treat hip and knee OA pain conducted in Europe and Japan.
Disclosures: The study was sponsored by Pfizer and Eli Lilly. Dr. Berenbaum disclosed receiving research funding through his institution from Pfizer and acting as a consultant to, and speaker for, the company as well as multiple other pharmaceutical companies. Coauthors of the study also disclosed research funding or consultancy agreements with Pfizer or Eli Lilly or were employees of the companies.
Berenbaum F et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):262-4. Abstract LB0007, doi: 10.1136/annrheumdis-2019-eular.8660.